Top Markets
Coin of the day
Intellipharmaceutics International Inc. Intellipharmaceutics International Inc.

Intellipharmaceutics International Inc.

IPCIF
Rank in Stocks #99999
Intellipharmaceutics International Inc., a pharmaceutical company, researches,... Intellipharmaceutics International Inc., a pharmaceutical company, researches, develops, and manufactures novel and generic controlled-release and targeted-release oral solid dosage drugs in the United States. It develops various drug delivery systems, product candidates, and a pipeline of products based on its patented Hypermatrix technology in various therapeutic areas, including neurology, cardiovascular, gastrointestinal tract, diabetes, and pain. The company offers Focalin XR, a dexmethylphenidate hydrochloride extended-release capsule for hyperactivity disorder; Keppra XR, a levetiracetam extended-release tablet for the treatment of partial onset seizures in patients with epilepsy; Effexor XR, a venlafaxine hydrochloride extended-release capsule to treat depression; and Protonix, a pantoprazole sodium delayed-release tablet to treat gastroesophageal reflux disease. It also provides Glucophage XR, a metformin hydrochloride extended-release tablet that treats type 2 diabetes; Seroquel XR, a quetiapine fumarate extended-release tablet for the treatment of schizophrenia, bipolar disorder, and major depressive disorders; Lamictal XR, a lamotrigine extended release tablet to treat epilepsy; Pristiq, a desvenlafaxine extended-release tablet to treat depression; Coreg CR, a carvedilol phosphate extended-release capsule for heart failure and hypertension; and Ranexa, a ranolazine extended release tablet for chronic angina. In addition, the company is developing OxyContin, an oxycodone hydrochloride controlled-release capsule for pain; OxyContin, an oxycodone hydrochloride controlled-release capsule for pain; and Regabatin XR, a pregabalin extended-release capsule for the management of neuropathic pain. It has a license and commercialization agreement with Par Pharmaceutical Inc. The company was founded in 1998 and is based in Toronto, Canada.
Share Price
$0.15
Market Cap
$4.96M
Change (1 day)
0.00%
Change (1 year)
0.00%
Country
CA
Trade Intellipharmaceutics International Inc. (IPCIF)

Category

Stock price history for Intellipharmaceutics International Inc. (IPCIF)
Highest end of day price: $0.15 on 2024-11-01

Lowest end of day price: $257.83 on 2009-10-01
Stock price history of Intellipharmaceutics International Inc. from 2009 to 2026
Annual Stock Price Performance
Year Performance
2024 115.80%
2023 -6.42%
2022 -39.73%
2021 -13.08%
2020 -62.82%
2019 52.02%
2018 -96.81%
2017 -71.95%
2016 34.10%
2015 -16.95%
2014 -27.81%
2013 48.05%
2012 -19.79%
2011 11.50%
2010 56.06%
2009 0.00%
Stock price for similar companies or competitors
Company Stock price Change 1y% Country
$36.40 -49.25%
DK
$453.74 -9.30%
US
$756.73 18.21%
US
$298.08 65.31%
BE
$692.83 18.70%
NL